Industry Trend Analysis - Government To Remain Committed To Restricting Pharmaceutical Spending - OCT 2017
BMI View : Momentum has been building behind German Chancellor Angela Merkel's Christian Democrats (CDU), which are set to win a plurality of seats at the federal election on September 24 2017. A strong showing at the ballot box would mean that the CDU has the upper hand in coalition negotiations to form a government, which would suggest a broadly similar policy agenda over the next five years. With regards to the pharmaceutical sector, while our core view is for another term for Merkel, regardless of who wins the election the German government will remain focused on controlling pharmaceutical expenditure.
With less than a month to go until the German Federal elections on September 24 2017, Chancellor Angela Merkel's ruling centre-right Christian Democratic Union (CDU) is on track to win a plurality of seats in the Bundestag. Regardless of who wins the election, the most controversial areas of German healthcare policy will continue to be the government's assessment of medicine cost-effectiveness and the methods it employs to control expenditure on steadily rising innovative medicines and technologies.
Cost Containment Measures Will Remain A Focus
|The Largest Pharmaceutical Market In Europe|
|Germany Pharmaceutical Market Forecast|
|f = BMI forecast. Source: The Federal Health Monitoring System (GBE-Bund), BMI|